TD Cowen analyst Dan Brennan raised the firm’s price target on Guardant Health (GH) to $130 from $100 and keeps a Buy rating on the shares. The firm adjusted targets in the diagnostics group as part of a Q4 preview. It expects solid results and 2026 outlooks for the sector, saying strong fundamentals remain.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- RBLX, META, GH, IONS: Cathie Wood Loads Up on Roblox, Trims Meta and Biotech Stocks
- Guardant Health management to meet virtually with BTIG
- TEM, KDK, PSNL: Cathie Wood Loads Up on AI Health Tech, Trims SHOP & ROKU
- Guardant Health price target raised to $115 from $85 at Guggenheim
- Evercore ISI upgrades four, downgrades six in MedTech and Tools